Gelesis Revenue and Competitors

Claim your profile

Boston, MA USA



Total Funding



Estimated Revenue & Valuation

  • Gelesis's estimated annual revenue is currently $15.8M per year.(i)
  • Gelesis's estimated revenue per employee is $188,214
  • Gelesis's total funding is $312.8M.

Employee Data

  • Gelesis has 84 Employees.(i)
  • Gelesis grew their employee count by -18% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Gelesis is a registrational-stage biotechnology company developing a novel category of first-in-class therapies for weight loss and GI-related diseases. Our platform uses a clinically validated hydrogel technology composed of naturally derived building blocks. The Gelesis portfolio includes a product for obesity and overweight and a pipeline with potential therapies for Non-alcoholic Fatty Liver Disease (NAFLD)/ Non-alcoholic Steatohepatitis (NASH), Type 2 diabetes and Chronic Idiopathic Constipation (CIC). Gelesis is headquartered in Boston, Mass. and was founded by PureTech Health and a group of leading obesity researchers. Gelesis is led by a strong management team, with expertise in medicine, materials science, manufacturing and commercialization. Our scientific advisory board and clinical advisors are leading experts in obesity and chronic disease. Community guidelines:



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Gelesis News

2022-04-20 - Gelesis' Proprietary Superabsorbent Hydrogel Induced ...

Gelesis' Proprietary Superabsorbent Hydrogel Induced Beneficial Changes to the Gut Microbiota and Expanded Akkermansia, a Bacterial Species...

2022-04-19 - Where Will Gelesis Holdings Inc (GLS) Stock Go Next After It Has Risen 9.73% in a Week?

Gelesis Holdings Inc (GLS) stock has risen 9.73% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

2022-04-13 - Gelesis Holdings: Advancing Biomimetic Superabsorbent Hydrogels For GI-Related Diseases

The Company is evaluating and investigating its technology in GI-related diseases. Gelesis consummated a business combination with an SPAC in...

2021-11-18 - Gelesis Receives $30 Million Plenity Order from Ro

Gelesis announced today that leading U.S. direct-to-patient healthcare company Ro has placed a $30 million fully paid pre-order for the company’s first commercial product for weight management, Plenity®. Plenity was initially made available through a beta launch in 2020, and demand quickly outpa ...

2021-11-18 - PureTech Founded Entity Gelesis Receives $30 Million Plenity® Order from Ro

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, announced today that its Founded Entity, Gelesis, Inc. (“Gelesis”) received a $30 million fully paid pre-order for the company’s first commercial product for weight management, ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding